Hikma Pharmaceuticals PLC (LON:HIK) Given Average Rating of “Buy” by Analysts

Hikma Pharmaceuticals PLC (LON:HIK) has been assigned a consensus recommendation of “Buy” from the six ratings firms that are covering the company, MarketBeat.com reports. Six research analysts have rated the stock with a buy recommendation. The average twelve-month price target among brokers that have issued a report on the stock in the last year is GBX 1,687.

A number of equities analysts have issued reports on the stock. Jefferies Financial Group lifted their price objective on shares of Hikma Pharmaceuticals from GBX 1,850 to GBX 1,870 and gave the stock a “buy” rating in a report on Tuesday, May 5th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a GBX 195 target price on shares of Hikma Pharmaceuticals in a report on Monday, June 22nd. Berenberg Bank reissued a “buy” rating and set a GBX 1,800 price target on shares of Hikma Pharmaceuticals in a research report on Tuesday, April 28th. Finally, Citigroup restated a “buy” rating on shares of Hikma Pharmaceuticals in a report on Thursday.

Hikma Pharmaceuticals Trading Up 1.9%

LON HIK opened at GBX 1,523.60 on Thursday. The firm has a market capitalization of £3.21 billion, a P/E ratio of 8.42, a PEG ratio of 2.38 and a beta of 0.65. The business has a fifty day simple moving average of GBX 1,487.53 and a 200 day simple moving average of GBX 1,448.63. Hikma Pharmaceuticals has a 12 month low of GBX 1,187 and a 12 month high of GBX 2,052. The company has a current ratio of 1.82, a quick ratio of 1.27 and a debt-to-equity ratio of 61.84.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.